Molbio Diagnostics earnings calls.

Molbio Diagnostics reported Q1 FY27 revenue of ₹48 croreCurrent reported value: ₹48 crore. No comparable prior figure is available in the source record. with EBITDA of ₹10.4 croreCurrent reported value: ₹10.4 crore. No comparable prior figure is available in the source record. (25Current reported value: 25. No comparable prior figure is available in the source record.% margin) and PAT of ₹5.27 croreCurrent reported value: ₹5.27 crore. No comparable prior figure is available in the source record.. The company, fresh from its IPO, is a point-of-care molecular diagnostics play with the proprietary TruNAT platform (12,500+Current 12,500+. Reported change: 90+ countries. machines globally, 30+ tests). The TB business dominates domestic revenues (~90%), with a newly renewed 2-year government contract. Key concerns include: device sales appearing to decline YoY (historically 2200-2600 annually), Optra Scan (digital pathology subsidiary) remaining loss-making through FY27 post-July FDA clearance, and limited visibility on HPV government program volumes. Management guided to ~25% revenue growth and 24-25% EBITDA for FY27 but acknowledged non-linear quarterly patterns. Test kit volumes (62.4 lakhCurrent 62.4 lakh. Reported change: Kit volumes higher than Q4 FY26. kits, 164 devices in Q1) showed mixed trends versus Q4. The bull case hinges on geographic expansion (Europe IVDR, US market entry), new disease tests (22 in pipeline), and non-communicable disease platform development (10x the infectious disease opportunity). Key risk: heavy TB program concentration with government funding cycles and potential pricing pressure from product mix shifts.